Unscheduled Cancer Pain Admissions Costly: Close to $5 Million a Year at M.D. Anderson

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

HOUSTON-Unscheduled hospital admissions for treatment of pain represent a significant cost-$4.7 million annually in a study from The University of Texas M.D. Anderson Cancer Center.

HOUSTON-Unscheduled hospital admissions for treatment of painrepresent a significant cost-$4.7 million annually in a studyfrom The University of Texas M.D. Anderson Cancer Center.

Monica M. Larsen, BA, of the Department of Pharmacoeconomics,who presented the abstract at the 8th World Congress on Pain,said that more effective outpatient pain interventions are thekey to reducing these expensive admissions.

Ms. Larsen and her colleagues reviewed the records of all patientsadmitted through the emergency care unit over a 6-month period.

Of the 1,166 total admissions, 14% were for pain, ranking secondonly to fever (35%). The reasons for the pain admissions werepain management (60%), abdominal pain (24%), chest pain (10%),headache (5%), and back pain (1%).

The mean length of stay for pain admissions was 10.5 days, andthe mean patient charge per admission was $19,000 ($1,800 perday).

Using the hospital-specific cost-to-charge ratio of 0.74, theresearchers determined that the actual hospital cost per admissionfor pain was $14,000 ($1,300 per day). Thus, they were able topredict an annual cost of about $4.7 million for unscheduled painadmissions.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Related Content